Program
goflikicept
Also written as “RPH-104”, “RPH-104 80 mg” and “RPH-104 320 mg”.
Its studies are mostly in Familial Mediterranean Fever · Pericarditis · Arthritis, Juvenile · Still's Disease, Adult-Onset · Paraproteinemias, led by R-Pharm.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| R-Pharm | 145 open or running | phase 3since May 6, 2020 | Jan 20, 2016 | Dec 14, 2027phase 3 · NCT07625384 |
Also a collaborator on its studies: unimed-laboratories, data-management-365, exacte-labs-llc, keystat-llc, cromos-pharma-llc, k-research-llc, center-of-pharmaceutical-analytics-llc, covance, oct-llc and monitorcro.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2016First study: phase 1 study in HealthyFirst studyNCT02667639 · 35 enrolled · Turkey
- Aug 5, 2019Phase 2 study in HyperuricemiaNCT04067492 · 47 enrolled · Russian Federation
- Oct 22, 2019Phase 2 study in Schnitzler SyndromeNCT04213274 · United States
- May 6, 2020Phase 3 study in COVID-19NCT04380519 · 372 enrolled · Russian Federation
- Jul 3, 2020Phase 2 study in ST Elevation Myocardial InfarctionNCT04463251 · 102 enrolled · United States, Russia
- Dec 29, 2020Phase 3 study in PericarditisNCT04692766 · 20 enrolled · Russian Federation
- Sep 9, 2021Phase 2 study in Familial Mediterranean FeverNCT05092776 · 84 enrolled · Armenia, Georgia, Russian Federation and more
- Oct 28, 2021Phase 3 study in PericarditisNCT05107934 · 80 enrolled · United States
- Nov 3, 2021Phase 2 study in Familial Mediterranean FeverNCT05190991 · 60 planned · Armenia, Russian Federation, Turkey
- Jun 21, 2022Phase 3 study in Still's Disease, Adult-OnsetNCT05432960 · Russian Federation
- Dec 21, 2022Phase 3 study in PericarditisNCT05673902 · 17 enrolled · Russian Federation
- Sep 26, 2025Phase 1 study in HealthyNCT07206043 · 130 enrolled · Russia
- May 19, 2026Phase 3 study in Arthritis, JuvenileNCT07625384 · 52 planned · Russia
- Oct 12, 2026Phase 3 study in Familial Mediterranean FeverNCT07880886 · 18 planned · Russia
Ahead
- Dec 14, 2027Primary completion: phase 3 study in Arthritis, JuvenileNCT07625384
- Dec 2028Primary completion: phase 2 study in Familial Mediterranean FeverNCT05190991
- May 2029Primary completion: phase 3 study in Familial Mediterranean FeverNCT07880886
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07880886Familial Mediterranean Fever · Russia | 3 | Not yet recruiting | May 2029 | 18 |
| NCT07625384Arthritis, Juvenile · Russia | 3 | Not yet recruiting | Dec 14, 2027 | 52 |
| NCT07206043Healthy · Russia | 1 | Completed | Feb 27, 2025 | 130 |
| NCT05673902Pericarditis · Russian Federation | 3 | Active, not recruiting | Jan 2026 | 17 |
| NCT05432960Still's Disease, Adult-Onset · Russian Federation | 3 | Withdrawn | Aug 2025 | 0 |
| NCT05190991Familial Mediterranean Fever · Armenia, Russian Federation, Turkey | 2 | Recruiting | Dec 2028 | 60 |
| NCT05107934Pericarditis · United States | 3 | Suspended | May 2027 | 80 |
| NCT05092776Familial Mediterranean Fever · Armenia, Georgia, Russian Federation and more | 2 | Active, not recruiting | Jan 2025 | 84 |
| NCT04692766Pericarditis · Russian Federation | 3 | Completed | Jan 24, 2022 | 20 |
| NCT04463251ST Elevation Myocardial Infarction · United States, Russia | 2 | Completed | Nov 3, 2021 | 102 |
| NCT04380519COVID-19 · Russian Federation | 3 | Completed | Jul 10, 2020 | 372 |
| NCT04213274Schnitzler Syndrome · United States | 2 | Withdrawn | Aug 2023 | 0 |
| NCT04067492Hyperuricemia · Russian Federation | 2 | Terminated | Mar 16, 2020 | 47 |
| NCT02667639Healthy · Turkey | 1 | Completed | Jun 2017 | 35 |
How it is read
Names in the registry
- “RPH-104”, 8 entries
- “RPH-104 80 mg”, 5 entries
- “RPH-104 320 mg”, 2 entries
- “Goflikicept”, 1 entry
- “RPH-104 160 mg”, 1 entry
Conditions, from the studies’ own filings
- Familial Mediterranean Fever, 3 studies
- Pericarditis, 3 studies
- Arthritis, Juvenile, 1 study
- Still's Disease, Adult-Onset, 1 study
- Paraproteinemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.